Understanding the development of neuropsychiatric disorders in young people with 22q11.2 deletion syndrome.
1/2: Neurodevelopmental Trajectories in 22q11.2 Deletion Syndrome in Adolescence and Young Adulthood
This study is looking at how having 22q11.2 deletion syndrome can influence the development of mental health issues like ADHD, anxiety, and autism as young people grow up, and it aims to understand the different factors that might affect their mental well-being over time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11034138 on NIH RePORTER |
What this research studies
This research investigates how 22q11.2 deletion syndrome affects the development of neuropsychiatric disorders during adolescence and young adulthood. It aims to identify the various developmental trajectories and risk factors associated with conditions like ADHD, anxiety, and autism spectrum disorders. By examining both genetic and environmental influences, the study seeks to provide a comprehensive understanding of how these factors contribute to mental health outcomes in affected individuals. Participants will be monitored over time to capture changes and patterns in their psychological development.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents and young adults aged 12 to 20 who have been diagnosed with 22q11.2 deletion syndrome.
Not a fit: Patients without a diagnosis of 22q11.2 deletion syndrome or those outside the age range of 12 to 20 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and management of neuropsychiatric disorders in patients with 22q11.2 deletion syndrome.
How similar studies have performed: Previous research has shown success in understanding neurodevelopmental trajectories in similar genetic conditions, indicating that this approach has potential for meaningful insights.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Gur, Raquel E — University of Pennsylvania
- Study coordinator: Gur, Raquel E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.